Eclampsia Preeclampsia
Conditions
Brief summary
Magnesium has built up the reputation of a 'natural calcium antagonist'. However, the exact effect of magnesium on coagulation and more specifically on platelet function is still disputed. An important discrepancy between in vivo and in vitro studies exists. Magnesium has thus been reported to antagonize platelets in some studies, and to stimulate platelets in other studies. Current evidence seems to point in the direction of a general antagonization of aggregation and coagulation. Intravenous magnesium is often administered in pre-eclampsia as seizure prophylaxis. Therapeutic regimens usually consist of an intravenously administered loading dose (2-3 grams) and a maintenance infusion, targeting a plasma level of 2-3 mmol/L. Therapeutic drug monitoring is needed, as magnesium toxicity is an important concern.
Interventions
OTHERCollect a study-specific blood sample of healthy subjects
One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
Sponsors
Maastricht University
Ziekenhuis Oost-Limburg
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Signed Informed consent * Over 18 years of age (and younger or equal to 50 years of age) and able to provide legally binding consent * American Society of Anesthesiologists physical fitness scale 1 (non smoker, no or minimal alcohol use, ..)
Exclusion criteria
* Chronic disease * Chronic medical therapy (other than oral contraception) * Pregnancy * ASA 2 or higher * Known coagulation or aggregation disorders * Use of COX-inhibitors in the last 10 days * Contra-indications for venipuncture
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PAC-t-UB test results | 4 months | The main endpoint of this study is the Platelet Activation Test in Unprocessed Blood (PAC-t-UB). |
Countries
Belgium
Outcome results
None listed